Short answer
Innoviva, Inc. (INVA) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $106M (down 1.6% year over year) with net income of −$74M.
Q3 2026 key financials · XBRL
- Revenue
- $106M
- −1.6% YoY · −11.3% QoQ
- Net income
- −$74M
- −182.2% YoY · +11.4% QoQ
- Operating margin
- 39.7%
- Gross margin
- 79.5%
- EPS (diluted)
- −$0.85
- −176.6% YoY · +12.4% QoQ
Source: XBRL data from the Innoviva, Inc. (INVA) Q3 2026 10-Q on SEC EDGAR. USD.
Innoviva, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $106.1M, down 1.6% YoY from $107.8M, with net product sales $49.4M
- Operating income $42.2M, up 21.9% YoY from $34.6M
- Best performer: U.S. XACDURO sales $16.1M, up $7.6M YoY; worst: ex-U.S. XERAVA sales $1.7M, down 91%
- Cash $581.4M; operating cash flow $129.0M vs $142.4M YoY; share repurchases $26.3M
- Near-term outlook: cash sufficient for at least 12 months; NUZOLVENCE commercialization focused on market access and distribution infrastructure
Risk Factors
- No material changes to 2025 Form 10-K risk factors
- Carried-forward risks remain the company’s primary disclosed exposures
- No new regulatory, legal, or compliance risk identified
- No new operational, competitive, or market risk identified
- No new liquidity, debt, currency, or concentration risk identified
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Innoviva, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.